CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy

被引：47

作者：

Murad, Yanal M.

Clay, Timothy M.

Lyerly, H. Kim

Morse, Michael A.

机构：

[1] Duke Univ, Med Ctr, Program Mol Therapeut, Ctr Comprehens Canc,Dept Surg, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Program Mol Therapeut, Duke Comprehens Canc Ctr,Dept Pathol & Immunol, Durham, NC 27710 USA

[3] Duke Univ, Med Ctr, Program Mol Therapeut, Comprehens Canc Ctr,Dept Med, Durham, NC 27710 USA

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2007年 / 7卷 / 08期

关键词：

adjuvant; CPG-7909; PF-3512676; ProMune; TLR9;

D O I：

10.1517/14712598.7.8.1257

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Stimulation of toll-like receptor (TLR)9 activates human plasmacytoid dendritic cells and B cells, and induces potent innate immune responses in preclinical tumor models and in patients. CpG oligodeoxynucleoticles (ODNs) are TLR9 agonists that show promising results as vaccine adjuvants and in the treatment of cancers, infections, asthma and allergy. PF-3512676 (ProMune((R))) was developed as a TLR9 agonist for the treatment of cancer as monotherapy and as an adjuvant in combination with chemo- and immunotherapy. Phase I and II trials have tested this drug in several hematopoietic and solid tumors. Pfizer has initiated Phase III trials to test PF-3512676 in combination with standard chemotherapy for non-small-cell lung cancer.

引用

页码：1257 / 1266

页数：10

共 50 条

[21] Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer
Manegold, Christian
Gravenor, Donald
Woytowitz, Donald
Mezger, Joerg
Hirsh, Vera
Albert, Gary
Al-Adhami, Mohammed
Readett, David
Krieg, Arthur M.
Leichman, Cynthia Gail
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) : 3979 - 3986
[22] Crohn's disease is associated with a toll-like receptor-9 polymorphism
Török, HP
Glas, J
Tonenchi, L
Bruennler, G
Folwaczny, M
Folwaczny, C
GASTROENTEROLOGY, 2004, 127 (01) : 365 - 366
[23] Toll-like Receptor-9 Gene Polymorphism in Common Variable Immunodeficiency
Tanir, S.
Karkucak, M.
Yakut, T.
Kilic, S. S.
JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2010, 20 (03) : 267 - 268
[24] The immune effects of Toll-like receptor-9 activation in hepatic fibrosis
Abu Tair, Lina F.
Axelrod, Jonathan H.
Doron, Sarit
Galun, Eithan
Amer, Johnny
Safadi, Rifaat
HEPATOLOGY, 2012, 56 : 772A - 772A
[25] PIVOTAL EFFECTS OF TOLL-LIKE RECEPTOR-9 ACTIVATION IN HEPATIC FIBROSIS
Amer, J.
Axelrod, J. H.
Khvalevsky, E.
Doron, S.
Abu Tair, L.
Nechemia, Y.
Galun, E.
Safadi, R.
JOURNAL OF HEPATOLOGY, 2010, 52 : S46 - S47
[26] Interferon-beta and Toll-Like Receptor-9 Processing Reply
Weiner, Howard
ANNALS OF NEUROLOGY, 2011, 69 (04) : 741 - 741
[27] Toll-like receptor-9 activation by CPG or P-DNA ameliorates hepatic fibrosis; Associated with lymphocyte alterations
Axelrod, J. H.
Khvalevsky, E.
Doron, S.
Erik, J.
Nechemia, Y.
Pappo, O.
Galun, E.
Safadi, R.
JOURNAL OF HEPATOLOGY, 2008, 48 : S20 - S20
[28] Toll-Like Receptor-9 Polymorphisms in Sarcoidosis and Chronic Obstructive Pulmonary Disease
Pabst, Stefan
Bradler, Oxana
Gillissen, Adrian
Nickenig, Georg
Skowasch, Dirk
Grohe, Christian
RESPIRATORY REGULATION - THE MOLECULAR APPROACH, 2013, 756 : 239 - 245
[29] Combination of a Toll-like receptor 9 (TLR9) agonist, CPG 7909 (CPG) with first line taxane/platinum improves response rate in late stage non-small-cell lung cancer (NSCLC)
Manegold, C
Mezger, J
Peschel, C
Leichman, G
Haarmann, C
Al-Adhami, M
Schmalbach, T
ANNALS OF ONCOLOGY, 2005, 16 : 306 - 306
[30] Chronic exposure to indoxacarb and pulmonary expression of toll-like receptor-9 in mice
Kaur, Sandeep
Mukhopadhyay, C. S.
Sethi, R. S.
VETERINARY WORLD, 2016, 9 (11) : 1282 - 1286

← 1 2 3 4 5 →